How BYU scientists struck pharmaceutical gold â and the fight over who keeps the money
For the past decade, scientists have been fighting over the proceeds from the massive settlement with Pfizer
(Illustration by Christopher Cherrington | The Salt Lake Tribune)
Editorâs note ⢠This story is available to Salt Lake Tribune subscribers only. Thank you for supporting local journalism.
One day in 2012, Weilin Xie got a call out of the blue telling him he had $1 million coming his way.
No, Xie had not won a lottery. His former professor, Brigham Young University biochemist Daniel Simmons, had called to tell him the money was for Xieâs participation 20 years earlier in research that led to the development of blockbuster anti-inflammatory drug Celebrex.
Unichem Laboratories gained 1.15% to Rs 280.85 after the company said it received US drug regulator s approval for celecoxib capsules, an anti-inflammatory drug.
In a regulatory filing made during market hours today, the company said that it had received ANDA approval for its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg from the United States Food and Drug Administration (US FDA). The product is a generic version of Celebrex capsules of G.D. Searle LLC, Division of Pfizer Inc.
Celecoxib capsules are indicated for treatment of osteoarthritis, rheumatoid arthritis juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain and primary dysmenorrhea. The product will be commercialized from Unichem s Goa Plant, the company said in a statement.
Key equity barometers hit fresh intraday low as selling intensified in mid-afternoon trade. At 14:24 IST, the barometer index, the S&P BSE Sensex, was down 233.96 points or 0.47% to 49,283.15. The Nifty 50 index lost 66.70 points or 0.46% to 14,496.75.
Investors continued to monitor the developments on the US political front as the US House of Representatives is expected to vote on an impeachment motion against President Trump today.
The broader market underperformed the benchmark indices. The S&P BSE Mid-Cap index fell 1.13%. The S&P BSE Small-Cap index slipped 0.79%.
Sellers outpaced buyers. On the BSE, 1051 shares rose and 1957 shares fell. A total of 149 shares were unchanged.
And parliament which has been basically a trial what about that argument? described as a rotten parliament that is a good argument. has consistently tried to derail that is how the constitution has brexit. that s exactly what happened today with this vote. set up this process. i think nancy pelosi will go having said that, i think this was actually a very close vote, along with this. if she needs to do more and it does bode well for the investigating and she thinks government if, indeed, the e.u. there are more witnesses that need to come forward, she will continue to investigate, and i agreement is put back before the don t think the republicans have much of an argument to make house of commons next week for a since they have been defying meaningful vote. i think that boris johnson would subpoenas and refusing to testify anyway, but given the actually win that vote if he is chief of staff s press conference the other day, i can allowed to do so by the speaker of the house of commons
joining us now vox s ezra klein, this story illustrates a big hole in the last round of health care reform which is no real controls on pharmaceutical prices. almost none at all. i think people really don t realize how unique america is in how we treat pharmaceuticals. we allow companies to set their own prices. other countries like canada, england or japan believe that because these drugs are life saving, and because the patient really doesn t have the ability to say no, often it s say yes or literally die, there needs to be some level of regulation. government needs to be the sort of prime negotiator. you have other countries where these drugs are on offer. you can get them there. to use a different example, celebrex which is a painkiller you can get in america, on average it costs about $250 for a round of it.